Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Wednesday, July 1

PSTE. ESON rc B 9 3218-321
~~LIjI

32188 Energy balance studies during growth hormone therapy
support a metabolic mechanism of action
Nicholas Paton*; PJ. Newton; H.M. Ross; J. Cotton; P Engrand;
B.J. Gazzard; G.E. Griffin, Singapore, UK
32189 Bartonella henselae serostatus is not correlated with
neurocognitive decline in HIV-infection
Mark Wallace*; R.K. Heaton; J.A. McCuthan; J.A. Nelson;
J. Magera; S.A. Tasker; I. Grant; D.H. Persing, USA
32190 Plasma viral load predicts cognitive function after one year
James Beckeer*; M.A Dew; 0.1 Lopez, USA
32191 Predictive markers for HIV-associated dementia and sensory
neuropathy
Elizabeth Childs*; Justin C. McArthur; R.H. Lyles; E. Miller; B.A. Cohen;
B.B. Chen; J. Mellors; J.C McArthur, USA
32192 Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex
(Study CNAB 3001)
Bruce James Brew*; S.J. Brown; J. Catalan; N. Sacktor; M. Halman;
WT Symonds; C. Romero; CNAB 001 Study Team, Australia
32193 Progressive multifocal leukoencephalopathy (PML) treatment with
cidofovir
Rustam Al-Shahi*; M. Sadler; E. Davies; M.R. Nelson; B.G. Gazzard, UK
32194 Progressive multifocal leucoencephalopathy in AIDS: Evolution with
antiretroviral treatment including protease inhibitors
Jacques Gasnault*; L. Kousignian; C Goujard; Y Taoufik;.EF Delfraissy,
France
32195 HIV-1 RNA, as measured by the Gen-ProbeTMA assay,
predicts neurocognitive outcomes as well as progression
to AIDS and death in HIV-infected patients
R. Haubrich*; R. Haubrich; J. Hwang; R.J. Ellis; J.A. McCutchan;
R. Heaton; S. Bodrug; E. Dise, USA
32196 Regression of neurocognitive impairment with protease
inhibitors-based regimens
Valero Tozzi*; S. Galgani; R Balestra; R Narciso; C D'amato; F Ferri;
F Pigorini, Italy
32197 Effect of ritonavir (RTV)/saquinavir(SQV) versus RTV/SQV/stavudine
(d4T) on cerebrospinal fluid (CSF) HIV-RNA levels: Preliminary results
Elisabeth H. Gisolf*; P Portegies; R. Hoetelmans; M.E. Van der Ende;
K. Brinkman; F de Wolf; S.A. Danner, The Netherlands
32198 Change in CSF RNA level correlates with the effects of maximal
antiretroviral therapy on HIV associated neurocognitive disorder
Scott Le Tendre; Ronald Ellis*; S.L. Le Tendre; R.K. Heaton;
J.H. Atkinson; J.A. McCutchan, USA
32199 The occurrence of progressive multifocal leukoencephalopathy (PML)
in HIV-infected persons taking highly active antiretroviral therapy
(HAART)
Carl J. Fichtenbaum*; Woraphot Tantisiviwat; P Tebas; D.B. Clifford;
W.G. Powderly; CJ. Fichtenbaum, USA
32200 Inflammatory cytokines and HIV-1 associated neurodegeneration:
Oncostatin-M produced by mononuclear cells from HIV-1 infected
individuals induce apoptosis of primary neurons
Fabrizio Ensoli*; F Fiorelli; M. Decristofaro; D. Santini-Muratori;
B. Vannelli; G. Luzi; F Aiuti, Italy

32201 Correlation between the viral load in cerebrospinal fluid (CSF),
plasma and CNS involvement in HIV patients
Tengiz Tsertsvadze*; N.T Gochitashvili; R. Sukhiashvili, Georgia
32202 Cerebrospinal Fluid HIV-1 RNA levels and efavirenz concentrations
in patients enrolled in clinical trials
Karen T Tashima*; A.M.C. Caliendo; M.A. Ahmad; J.M.G. Gormley;
TFR Flanigan; W.D.F Fiske, USA
32203 Distribution of brain HIV load in AIDS
Clayton Wiley*; V Soontornniyomkis; C Achim; I. Mellors; E. Masliah;
S. Hermann; P Dailey, USA
32204 In vivo proton MRS studies of HIV brain injury and HIV dementia
Bradford Navia*; L. Lee; T Ernst; C. Yiannoutsos;J. Jarvik; C Marra;
D. Meyerhoff; R. Price; D. Simpson; S. Atlas; U. Patel; G. Schifitto;
S. Swindells; J. McConnell; R. Omaha; J. Videen; R. McKendall; L. Ketonen;
K. Goodkin; T Naidich; J. Post; D. Kolson; L. Chang; R. Lenkinski;
R.G. Gonzalez, USA
32205 Oligosymptomatic neurological patients in a cohort of HTLV-I infected
people
Abelardo Araujo*; A.CC Leite; E.S. Neves; A.L.A. Oliveira; CR. Afonso;
O.J.M. Nascimento, Brazil
32206 Symptoms and signs of peripheral neuropathy in HIV-infected children
Alexandra Araujo, Brazil
32207 Stavudine stops neuro-AIDS in AZT-non-responders
Gabriele Arendt*; H.-J. v. Giesen; H.Jablonowski, Germany
32208 Neurocognitive complications in HIV
Igor Grant*; R.K. Heaton; R.O. Ellis; E. Masliah; TD. Marcotte; L.K. Dawson;
AJ. McCutchan, USA
32209 Regression or stabilization of PML by Highly Active Antiretroviral
Therapy (HAART) and Acyclovir Therapy
Alberto Acosta, USA
32210 Detection of JC virus (JCV) DNA in blood cell subpopulations and plasma
of HIV+ individuals and HIV- controls with and without progressive
multifocal leukoencephalopathy (PML)
Igor J. Koralnik*; J.E. Schmitz; D. Boden; V Mai; N.L. Letvin, USA
32211 Latency of Event-Related Brain Potential P3a is Associated with Cognitive
Impairment in HIV Disease
Daniel Fletcher*; R. Bitner; K. McCallin; G. Fein, USA
NOTES

CONFERENCE WORKBOOK

141